WordNet

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人T細胞性白血病/リンパ腫の治療および予後 treatment and prognosis of adult t cell leukemia lymphoma
2. マイトマイシン-Cの肺毒性 mitomycin c pulmonary toxicity
3. 抵抗性または再発性の妊娠性絨毛腫瘍のマネージメント management of resistant or recurrent gestational trophoblastic neoplasia
4. 治療関連骨髄腫瘍：急性骨髄性白血病および骨髄異形成症候群 therapy related myeloid neoplasms acute myeloid leukemia and myelodysplastic syndrome
5. ステージIII非小細胞肺癌のマネージメント management of stage iii non small cell lung cancer

Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.

Arakelyan N, Jais JP, Tomowiack C, Colombat P, Berthou C, Desablens B, Moles-Moreau MP, Gastinne T, Quittet P, Casassus P, Le Pourhiet-Le Mevel A, Ghandour C, Brière J, Colonna P, Andrieu JM.SourceMolecular Oncology and Virology Laboratory, Paris-Descartes University, Paris, France.
Leukemia & lymphoma.Leuk Lymphoma.2013 Jan;54(1):76-82. doi: 10.3109/10428194.2012.701737. Epub 2012 Jul 9.
The H97-I trial (1997-2004) for Hodgkin lymphoma at intermediate stage (HL-I) included 269 patients who were randomized to receive three or four cycles of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD). The 197 patients who reached complete remission (CR) (73.2%, p = 0.41 between arms) r
PMID 22680774

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).

Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C.SourceDepartment of Oncology, University Hospital, Lausanne, Switzerland.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.Ann Oncol.2012 Dec 12. [Epub ahead of print]
BackgroundThe superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previo
PMID 23235801

Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China.

Hou Y, Wang HQ, Ba Y.SourceDepartment of Lyphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Medical oncology (Northwood, London, England).Med Oncol.2012 Dec;29(4):2372-8. doi: 10.1007/s12032-012-0184-1. Epub 2012 Mar 20.
To compare the efficacy and safety of RFT (retuximab, fludarabine, pirarubicin) with RCTVP (retuximab, cyclophophamide, pirarubicin, vindesine and prednisone) in 248 indolent B-cell non-Hodgkin's lymphoma (NHL) patients. Two hundred and forty-eight patients with indolent B-cell NHL were treated with
PMID 22430608